In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
About a month after rejecting a $380mm unsolicited bid to be acquired by Genzyme, AnorMed (therapeutics for cancer, blood disorders, and HIV) was offered $515mm by Millennium Pharmaceuticals. Under the Genzyme deal, shareholders would have received $8.55 apiece (a 54% premium to the then-market average); the Millennium deal would have paid out $12 for each share (a 21% premium based on the current market average).
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?